Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.

2.

Prior authorizations draining time, energy from many cancer patients

3.

FDA Expands Approval of Osimertinib in Lung Cancer

4.

Increased detection of adenomas may reduce colon cancer risk after colonoscopy in FIT-based screening.

5.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot